342 related articles for article (PubMed ID: 28537861)
1. Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report.
Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J; Liao W
Dermatol Online J; 2017 May; 23(5):. PubMed ID: 28537861
[TBL] [Abstract][Full Text] [Related]
2. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
Volf EM; Au SC; Dumont N; Scheinman P; Gottlieb AB
J Drugs Dermatol; 2012 Mar; 11(3):341-6. PubMed ID: 22395585
[TBL] [Abstract][Full Text] [Related]
3. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
4. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Moustafa F; Feldman SR
Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
[TBL] [Abstract][Full Text] [Related]
5. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
[TBL] [Abstract][Full Text] [Related]
7. Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
Schafer PH; Adams M; Horan G; Truzzi F; Marconi A; Pincelli C
Drugs R D; 2019 Dec; 19(4):329-338. PubMed ID: 31598889
[TBL] [Abstract][Full Text] [Related]
8. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Sobell JM; Foley P; Toth D; Mrowietz U; Girolomoni G; Goncalves J; Day RM; Chen R; Yosipovitch G
Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
[TBL] [Abstract][Full Text] [Related]
9. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
Samrao A; Berry TM; Goreshi R; Simpson EL
Arch Dermatol; 2012 Aug; 148(8):890-7. PubMed ID: 22508772
[TBL] [Abstract][Full Text] [Related]
11. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 4 inhibitors.
Zebda R; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
[TBL] [Abstract][Full Text] [Related]
13. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study.
Hanifin JM; Ellis CN; Frieden IJ; Fölster-Holst R; Stein Gold LF; Secci A; Smith AJ; Zhao C; Kornyeyeva E; Eichenfield LF
J Am Acad Dermatol; 2016 Aug; 75(2):297-305. PubMed ID: 27189825
[TBL] [Abstract][Full Text] [Related]
14. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
16. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
Danesh MJ; Beroukhim K; Nguyen C; Levin E; Koo J
Dermatol Online J; 2015 Jun; 21(6):. PubMed ID: 26158370
[TBL] [Abstract][Full Text] [Related]
17. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
Armstrong A; Levi E
J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
[TBL] [Abstract][Full Text] [Related]
18. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
Torres T; Puig L
Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
[TBL] [Abstract][Full Text] [Related]
19. Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
Nguyen CM; Leon A; Danesh M; Beroukhim K; Wu JJ; Koo J
J Drugs Dermatol; 2016 Mar; 15(3):272-6. PubMed ID: 26954311
[TBL] [Abstract][Full Text] [Related]
20. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Papp K; Reich K; Leonardi CL; Kircik L; Chimenti S; Langley RG; Hu C; Stevens RM; Day RM; Gordon KB; Korman NJ; Griffiths CE
J Am Acad Dermatol; 2015 Jul; 73(1):37-49. PubMed ID: 26089047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
